摘要 ： 多浦乐2025上半年营收增长56.19%，净利润增长12.15%，研发投入占比28.02%，积极开拓新市场并深耕核心技 术。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，广州多浦乐电子科技股份有限公司（以下简称"多浦乐"）发布了2025年半年度报告，交出了一份亮眼的"期中 成绩单"。报告显示， 公司实现营业收入7998.51万元，较上年同期大幅增长56.19%；实现归属于上市公司股东的 净利润1903.76万元，同比增长12.15% 。 保持技术研发优势： 公司作为核心单位参与多项国家级研发项目，先后承担了"相控阵超声检测系统"及"超声成像工 业无损检测仪"等国家研发项目，面向科研院所、高校以及航天航空、 核电等行业的复杂检测需求，开展高性能超声 相控阵检测设备及模块研制，以期实现更高效、更精准的检测效果。 多浦乐表示，未来将继续依托技术积累和市场拓展能力，推动无损检测设备在更多高端工业领域的创新应用，提升公司 在全球市场的竞争力。 点击文末"阅读原文"查看详情 多浦乐是一家专业从事无损检测设备研发、生产和销售的高新技术 ...

Core Viewpoint - Guangzhou Duople Technology Co., Ltd. has established a new subsidiary, Beijing Duople Innovation Technology Co., Ltd., with a registered capital of 30 million RMB, aiming to deepen industry layout and expand the North China market for long-term development [1][2]. Company Overview - Beijing Duople Innovation was founded on August 8, 2025, with a registered capital of 30 million RMB, located in the Yanqi Economic Development Zone, Huairou District, Beijing. The legal representative is Qian Chunming, and its business scope includes technical services, technology development, manufacturing and sales of instruments and meters, electronic components, software development, and import-export of goods [3][4]. - The shareholding structure includes Guangzhou Duople contributing 9 million RMB for a 30% stake, while individual investors contribute 5.25 million RMB each for a 17.5% stake [5]. Strategic Impact - The establishment of the subsidiary is part of the company's strategic development needs, aimed at enhancing market coverage and sales efficiency through specialized products and services, thereby promoting sustainable long-term growth [4][6]. - The investment is not expected to significantly impact the company's financial status or operational results for the current year, and it does not harm the interests of the company or its shareholders [4]. Business Focus - Guangzhou Duople is a high-tech enterprise specializing in the research, development, and manufacturing of ultrasonic equipment, systems, and transducers. The company aims to build a world-class non-destructive testing brand and was successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market on August 28, 2023, with stock code 301528 [7]. - The main products include industrial ultrasonic phased array testing equipment, automated testing devices, ultrasonic transducers, customized testing analysis software, and other supporting components, covering a full chain of business solutions and training services across various sectors [7].

Core Viewpoint - The deep localization of medical device manufacturing in China is becoming a key competitive advantage for domestic companies, driven by trade tensions and the need for innovation [1][7]. Group 1: Industry Changes - The trade friction has created opportunities for domestic medical device companies to replace imports, particularly in high-performance piezoelectric materials [1][3]. - Major international companies like GE Healthcare and Siemens are increasingly localizing their production in China to maintain market position amid rising competition from domestic firms [7][6]. - The domestic market for medical imaging equipment is evolving, with companies like New Hong Electronics developing products that can compete with established international brands [4][5]. Group 2: Market Dynamics - The price increase of transducers in the U.S. is prompting American medical device companies to seek local suppliers in China, presenting an opportunity for Chinese firms to enter the international supply chain [3][6]. - The market share of imported high-end X-ray tubes is around 85%, indicating significant room for growth for domestic manufacturers [5]. - The Chinese market for mid-to-low-end X-ray tubes has a localization rate of approximately 30%-40%, suggesting that there is still potential for further domestic production [5]. Group 3: Innovation and Collaboration - Companies are encouraged to focus on material and technological innovation rather than relying solely on tariff barriers for competitive advantage [10]. - Collaborative research and development between domestic companies and hospitals is essential for validating new technologies and products in the medical imaging sector [5][4]. - The need for continuous investment in research and development is highlighted as crucial for maintaining competitiveness in the medical device industry [10]. Group 4: Future Outlook - The ongoing U.S.-China trade tensions are expected to have a long-term impact on multinational companies and Chinese enterprises, creating a sustained push for deep localization [9][10]. - The medical device sector is seen as a strong regulatory environment where rapid technological change is more challenging compared to other industries like photovoltaics and batteries [9][8]. - The establishment of a robust ecosystem of domestic suppliers and innovation is critical for the future success of Chinese medical device companies [7][10].

Core Viewpoint - The recent shareholding changes and performance decline of Duopule (301528.SZ) have raised investor concerns, particularly regarding the confidence of major shareholders in the company's future prospects [2][3][4]. Shareholder Changes - Major shareholder Cai Shuping plans to reduce his holdings by up to 1.238 million shares, representing 2% of the total share capital, within three months starting from June 4, 2025 [3][4]. - This follows a previous reduction completed in January 2025, where Cai sold 537,200 shares at an average price of 44.59 yuan per share, raising approximately 23.95 million yuan [4]. - Another significant shareholder, Xiamen Rongyu, along with its action-in-concert party Suzhou Rongyu, plans to collectively reduce their holdings by up to 3 million shares, or 4.85% of the total share capital, from May 20 to August 17, 2025 [5]. Financial Performance - Duopule's revenue for 2023 was 199 million yuan, a year-on-year decline of 1.41%, with net profit dropping by 8.88% to 77.81 million yuan [7]. - In 2024, revenue further decreased to 162 million yuan, down 18.70%, and net profit fell by 33.68% to 51.60 million yuan [7]. - The company reported a significant increase in revenue in Q1 2025, achieving 38.49 million yuan, a year-on-year growth of 125.44%, but the gross margin decreased by 6.25% [8]. Industry Context - Duopule operates in a technology-intensive sector focused on non-destructive testing equipment, which requires high levels of R&D investment to maintain competitiveness [6]. - The company invested 38.40 million yuan in R&D in 2024, a 13.94% increase from the previous year, accounting for 23.70% of its revenue [6]. - The domestic non-destructive testing equipment industry is still in a growth phase, with a domestic market penetration rate of 52% as of 2023, but high-end products are predominantly supplied by foreign companies [6][8]. Strategic Developments - Duopule is actively expanding into the medical sector, having invested in companies related to medical ultrasound technology, although these initiatives are currently in the investment phase and have not yet contributed significantly to revenue [8][9].

Group 1 - Huaying Medical, a company with core component autonomy in ultrasound technology, has completed a new round of financing led by Nanshan Venture Capital, with participation from existing shareholder Shanghai Ke Investment [1] - Founded in 2020 and incubated by the Shenzhen Institute of Advanced Technology, Huaying Medical specializes in ultrasound transducer technology, active interventional catheter technology, and high-frequency ultrasound imaging systems, making it one of the few companies capable of mastering the entire ultrasound technology chain [1][2] - The company has a strong technical foundation backed by the Chinese Academy of Sciences and has undertaken significant ultrasound-related projects, showcasing deep technical reserves in innovative applications such as ultrasound catheter imaging and ultrasound therapy [2] Group 2 - The rise of precision treatment is driving rapid development in intracardiac imaging (ICE), with Huaying Medical positioned to leverage its full-chain autonomous technology for transducer localization, achieving cost reduction while maintaining stability [3] - Huaying Medical has completed product development for 4D-ICE, which enhances visualization in structural heart procedures, and possesses comprehensive core technologies for 4D-ICE, including imaging probes and algorithms [3] - The company is expanding its applications in ultrasound beyond imaging, breaking import monopolies with several exclusive domestic products in areas such as ultrasound liquid handling and high-frequency imaging devices [4] Group 3 - Investors express confidence in Huaying Medical's ability to address domestic procurement challenges and provide high-quality imaging solutions, particularly in the context of 4D-ICE technology [5] - The company has established a national high-tech platform for high-frequency medical ultrasound technology, with significant funding aimed at developing advanced ultrasound products [6] - Nanshan Venture Capital and Shanghai Ke Investment highlight the company's strong technical foundation and diverse product pipeline, positioning it as a potential industry leader in ultrasound technology [7][8]

导读： 多浦乐2024年实现营业收入1.62亿元，同比下降18.70%；归属于上市公司股东的净利润为0.52亿元，同比下降33.68%。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，广州多浦乐电子科技股份有限公司（简称：多浦乐）发布了2 0 2 4年度报告。报告显示，多浦乐全年实现营业收入1 . 6 2亿元，同比下降 1 8 . 7 0%；归属于上市公司股东的净利润为0 . 5 2亿元，同比下降3 3 . 6 8%。尽管业绩承压，多浦乐在技术创新和市场拓展方面持续发力，未来战 略聚焦医疗领域和自动化检测设备，力争实现业务多元化发展。 2 0 2 4年，多浦乐的收入主要来源于工业无损检测设备、超声换能器及配套零部件的销售。其中，工业无损检测设备实现营业收入7 , 0 4 5 . 1 9万 元，同比下降2 7 . 1 8%；超声换能器收入5 , 6 7 3 . 9 9万元，同比下降11 . 3 7%；配套零部件收入3 , 2 1 5 . 1 7万元，同比下降8 . 0 8%。 公司表示，营收下滑的主要原因是国内经济增速放缓导致 ...

股票简称：多浦乐 股票代码：301528 广州多浦乐电子科技股份有限公司 Guangzhou Doppler Electronic Technologies Co., Ltd. （广州经济技术开发区开创大道 1501 号 2 栋一楼） 首次公开发行股票并在创业板上市 之上市公告书 保荐人（主承销商） （深圳市福田区福田街道金田路 2026 号能源大厦南塔楼 10-19 层） 二〇二三年八月 广州多浦乐电子科技股份有限公司 上市公告书 特别提示 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新 股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词的释义与本公司首次公开发行 股票并在创业板上市招股说明书中的相同。如本上市公告书中合计数与各数直接 相加之和在尾数上存在差异，系由于四舍五入所致。 2 | | | 广州多浦乐电子科技股份有限公司（以下简称"多浦乐"、"公司"或"发行人"） 股票将于 2023 年 8 月 28 日在深圳证券交易所创业板市场上市。 创业板公司具有创新投入大、新旧产业融合存在不确定性、尚处于成长期、 经营风险高、业绩不稳定、退市 ...

创业板投资风险提示 本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业 融合存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高 等特点，投资者面临较大的市场风险。投资者应充分了解创业板的投资风险 及本公司所披露的风险因素，审慎作出投资决定。 保荐机构（主承销商） （深圳市福田区福田街道金田路 2026 号能源大厦南塔楼 10-19 层） 招股说明书 广州多浦乐电子科技股份有限公司 Guangzhou Doppler Electronic Technologies Co., Ltd. （广州经济技术开发区开创大道 1501 号 2 栋一楼） 首次公开发行股票并在创业板上市 招股说明书 本公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程序。本 招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当 以正式公告的招股说明书作为投资决定的依据。 声明及承诺 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对注册 申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之 相反的 ...

广州多浦乐电子科技股份有限公司 首次公开发行股票并在创业板上市发行公告 保荐人（主承销商）：长城证券股份有限公司 特别提示 广州多浦乐电子科技股份有限公司（以下简称"多浦乐"、"发行人"或"公 司"）根据中国证券监督管理委员会（以下简称"中国证监会"）颁布的《证券发 行与承销管理办法》（证监会令[第 208 号]）（以下简称"《管理办法》"）、《首次公 开发行股票注册管理办法》（证监会令[第 205 号]），深圳证券交易所（以下简称 "深交所"）颁布的《深圳证券交易所首次公开发行证券发行与承销业务实施细则》 （深证上[2023]100 号）（以下简称"《业务实施细则》"）、《深圳市场首次公开发行 股票网上发行实施细则》（深证上[2018]279 号）（以下简称"《网上发行实施细 则》"）、《深圳市场首次公开发行股票网下发行实施细则（2023 年修订）》（深证上 [2023]110 号）（以下简称"《网下发行实施细则》"），中国证券业协会（以下简称 "证券业协会"）颁布的《首次公开发行证券承销业务规则》（中证协发[2023]18 号）、 《首次公开发行证券网下投资者管理规则》（中证协发[2023]19 号）（以 ...

创业板投资风险提示 本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业融 合存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高等 特点，投资者面临较大的市场风险。投资者应充分了解创业板的投资风险及 本公司所披露的风险因素，审慎作出投资决定。 广州多浦乐电子科技股份有限公司 Guangzhou Doppler Electronic Technologies Co., Ltd. （广州经济技术开发区开创大道 1501 号 2 栋一楼） 首次公开发行股票并在创业板上市 招股意向书 本公司的发行申请尚需经深圳证券交易所和中国证监会履行相应程序。本 招股意向书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当 以正式公告的招股意向书作为投资决定的依据。 保荐机构（主承销商） （深圳市福田区福田街道金田路 2026 号能源大厦南塔楼 10-19 层） 招股意向书 声明及承诺 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对注册 申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之 相反的 ...